Latest News about AMGN
Recent news which mentions AMGN
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
October 06, 2023
From Benzinga
From Benzinga
From Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
October 03, 2023
From Benzinga
As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment
September 29, 2023
From MarketWatch
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
September 28, 2023
From InvestorPlace
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
September 27, 2023
From Benzinga
From MarketWatch
If you think stocks have gotten too expensive, this ETF’s strategy may work for your portfolio
September 26, 2023
From MarketWatch
Wall Street analysts expect the S&P 500 to rise 19% over the next 12 months. Here are their 10 favorite stocks.
September 26, 2023
From MarketWatch
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023
From Benzinga
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
From Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
From Benzinga
Why Shares of Neumora Therapeutics Slumped This Week
September 21, 2023
From Motley Fool
2 Dividend Growth Stocks to Buy Right Now
September 21, 2023
From Motley Fool
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
September 13, 2023
Tickers
AMGN
From Benzinga
2 Top Dividend Stocks to Buy in September
September 13, 2023
From Motley Fool
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
September 13, 2023
From Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
September 12, 2023
From InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
September 11, 2023
From Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 11, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
From Benzinga
These four Dow stocks take top prizes for dividend growth
September 06, 2023
From MarketWatch
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
September 05, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
|
|
|
|
|
|